Up to 25% of patients with ALK-rearranged non-small cell lung cancer (NSCLC) experience disease progression within the first year of targeted therapy. This work reports a phase 2 trial investigating whether combining alectinib with bevacizumab can delay resistance mechanisms in advanced ALK-rearranged NSCLC.
- Oscar Arrieta
- Luis Lara-Mejía
- Rafael Rosell
